Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
Int J Parasitol ; 46(5-6): 343-50, 2016 05.
Article in English | MEDLINE | ID: mdl-26953255

ABSTRACT

Repeated treatments with praziquantel reduce schistosomiasis prevalence and morbidity, but transmission persists and populations often recover within a few years. To identify factors associated with persistence, we surveyed and treated all identified Schistosoma mansoni infections in two rural Brazilian communities (Jenipapo and Volta do Rio) in 2009, 2012 and 2013. Eggs were collected from all infected individuals and genotyped with 11 microsatellite markers to evaluate parasite differentiation and diversity. After successive rounds of community-wide treatment, prevalence decreased from 45% to 24% then 16%. Intensity of infection decreased by 57% over this period, and the number of eggs transmitted to the environment decreased by 92%. During all time periods the majority of eggs were excreted by those >15years of age. The incidence was 23% in 2012 and 15% in 2013, consistent with a decrease in transmission. There was little immigration or gene flow over a distance of 6km. On reinfection, infrapopulations were moderately differentiated indicating that pretreatment multilocus genotypes were not fully reacquired. The effective population size responded to census population decline more rapidly than differentiation. Reinfection was concentrated in the downstream portion of Jenipapo, consistent with the observed increased human fecal contamination. At this scale and in this area S. mansoni infections exist on a fragmented landscape with a highly focal pattern of transmission that may facilitate future elimination.


Subject(s)
Anthelmintics/administration & dosage , Praziquantel/administration & dosage , Schistosoma mansoni/drug effects , Schistosomiasis mansoni/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Animals , Anthelmintics/pharmacology , Anthelmintics/therapeutic use , Brazil/epidemiology , Child , Child, Preschool , Feces/parasitology , Female , Gene Frequency , Genotyping Techniques , Humans , Incidence , Infant , Longitudinal Studies , Male , Microsatellite Repeats , Middle Aged , Parasite Egg Count , Praziquantel/pharmacology , Praziquantel/therapeutic use , Prevalence , Risk Factors , Rural Population , Schistosoma mansoni/classification , Schistosoma mansoni/genetics , Schistosomiasis mansoni/epidemiology , Schistosomiasis mansoni/transmission , Young Adult
2.
PLoS Negl Trop Dis ; 9(3): e0003521, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25775457

ABSTRACT

Urbanization is increasing across the globe, and diseases once considered rural can now be found in urban areas due to the migration of populations from rural endemic areas, local transmission within the city, or a combination of factors. We investigated the epidemiologic characteristics of urban immigrants and natives living in a neighborhood of Salvador, Brazil where there is a focus of transmission of Schistosoma mansoni. In a cross-sectional study, all inhabitants from 3 sections of the community were interviewed and examined. In order to determine the degree of parasite differentiation between immigrants and the native born, S. mansoni eggs from stools were genotyped for 15 microsatellite markers. The area received migrants from all over the state, but most infected children had never been outside of the city, and infected snails were present at water contact sites. Other epidemiologic features suggested immigration contributed little to the presence of infection. The intensity and prevalence of infection were the same for immigrants and natives when adjusted for age, and length of immigrant residence in the community was positively associated with prevalence of infection. The population structure of the parasites also supported that the contribution from immigration was small, since the host-to-host differentiation was no greater in the urban parasite population than a rural population with little distant immigration, and there had been little differentiation in the urban population over the past 7 years. Public health efforts should focus on eliminating local transmission, and once eliminated, reintroduction from distant migration is unlikely.


Subject(s)
Emigration and Immigration , Schistosomiasis/epidemiology , Adult , Animals , Brazil/epidemiology , Cross-Sectional Studies , Feces/parasitology , Female , Humans , Male , Middle Aged , Prevalence , Schistosoma mansoni/genetics , Schistosomiasis/etiology , Urban Population
3.
Eur Urol ; 66(5): 936-48, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25047176

ABSTRACT

BACKGROUND: Candidate biomarkers have been identified for clear cell renal cell carcinoma (ccRCC) patients, but most have not been validated. OBJECTIVE: To validate published ccRCC prognostic biomarkers in an independent patient cohort and to assess intratumour heterogeneity (ITH) of the most promising markers to guide biomarker optimisation. DESIGN, SETTING, AND PARTICIPANTS: Cancer-specific survival (CSS) for each of 28 identified genetic or transcriptomic biomarkers was assessed in 350 ccRCC patients. ITH was interrogated in a multiregion biopsy data set of 10 ccRCCs. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Biomarker association with CSS was analysed by univariate and multivariate analyses. RESULTS AND LIMITATIONS: A total of 17 of 28 biomarkers (TP53 mutations; amplifications of chromosomes 8q, 12, 20q11.21q13.32, and 20 and deletions of 4p, 9p, 9p21.3p24.1, and 22q; low EDNRB and TSPAN7 expression and six gene expression signatures) were validated as predictors of poor CSS in univariate analysis. Tumour stage and the ccB expression signature were the only independent predictors in multivariate analysis. ITH of the ccB signature was identified in 8 of 10 tumours. Several genetic alterations that were significant in univariate analysis were enriched, and chromosomal instability indices were increased in samples expressing the ccB signature. The study may be underpowered to validate low-prevalence biomarkers. CONCLUSIONS: The ccB signature was the only independent prognostic biomarker. Enrichment of multiple poor prognosis genetic alterations in ccB samples indicated that several events may be required to establish this aggressive phenotype, catalysed in some tumours by chromosomal instability. Multiregion assessment may improve the precision of this biomarker. PATIENT SUMMARY: We evaluated the ability of published biomarkers to predict the survival of patients with clear cell kidney cancer in an independent patient cohort. Only one molecular test adds prognostic information to routine clinical assessments. This marker showed good and poor prognosis results within most individual cancers. Future biomarkers need to consider variation within tumours to improve accuracy.


Subject(s)
Biomarkers, Tumor/genetics , Carcinoma, Renal Cell/genetics , Carcinoma, Renal Cell/pathology , Kidney Neoplasms/genetics , Kidney Neoplasms/pathology , Aged , Biopsy , Carcinoma, Renal Cell/mortality , DNA Mutational Analysis , Female , Gene Expression Profiling/methods , Gene Expression Regulation, Neoplastic , Genetic Predisposition to Disease , Humans , Kaplan-Meier Estimate , Kidney Neoplasms/mortality , Male , Middle Aged , Multivariate Analysis , Mutation , Neoplasm Staging , Phenotype , Polymorphism, Single Nucleotide , Predictive Value of Tests , Proportional Hazards Models , Reproducibility of Results , Risk Factors , Time Factors , Transcriptome
4.
Nat Genet ; 46(3): 225-233, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24487277

ABSTRACT

Clear cell renal carcinomas (ccRCCs) can display intratumor heterogeneity (ITH). We applied multiregion exome sequencing (M-seq) to resolve the genetic architecture and evolutionary histories of ten ccRCCs. Ultra-deep sequencing identified ITH in all cases. We found that 73-75% of identified ccRCC driver aberrations were subclonal, confounding estimates of driver mutation prevalence. ITH increased with the number of biopsies analyzed, without evidence of saturation in most tumors. Chromosome 3p loss and VHL aberrations were the only ubiquitous events. The proportion of C>T transitions at CpG sites increased during tumor progression. M-seq permits the temporal resolution of ccRCC evolution and refines mutational signatures occurring during tumor development.


Subject(s)
Carcinoma, Renal Cell/genetics , Kidney Neoplasms/genetics , Mutation , Class I Phosphatidylinositol 3-Kinases , CpG Islands , DNA Copy Number Variations , DNA-Binding Proteins , Disease Progression , Evolution, Molecular , Exome , Genomics , High-Throughput Nucleotide Sequencing , Histone-Lysine N-Methyltransferase/genetics , Humans , Nuclear Proteins/genetics , Phosphatidylinositol 3-Kinases/genetics , Phylogeny , Polymorphism, Single Nucleotide , Transcription Factors/genetics , Tumor Suppressor Proteins/genetics , Ubiquitin Thiolesterase/genetics , Von Hippel-Lindau Tumor Suppressor Protein/genetics
5.
Phytother Res ; 27(6): 916-25, 2013 Jun.
Article in English | MEDLINE | ID: mdl-22933368

ABSTRACT

Cissampelos sympodialis Eichl. (Menispermaceae) root infusion is used in Northeast Brazil to treat allergic asthma. We have previously shown that oral use of the plant extract reduces eosinophil infiltration into the lung of ovalbumin (OVA)- sensitized mice. However, drugs taken by inhalation route to treat asthma achieve better outcomes. Thereby, in this study, we evaluated the inhaled C. sympodialis alcoholic extract as a therapeutic treatment in OVA-sensitized BALB/c mice. The parameters which were analyzed consisted of leukocyte recruitment to the airway cavity, tissue remodeling and cell profile. The inhaled extract inhibited mainly eosinophil recruitment to the pleural cavity, bronchoalveolar lavage and peripheral blood. This treatment reduced the OVA-specific IgE serum titer and leukocyte infiltration in the peribronchiolar and pulmonary perivascular areas as well as mucus production. In addition, we also tested isolated alkaloids from the plant extract. The flow cytometric analysis showed that methylwarifteine (MW) and, mainly, the inhaled extract reduced the number of CD3+T cells and eosinophil-like cells. Therefore, inhaled C. sympodialis extract and MW lead to down-regulation of inflammatory cell infiltration with remarkable decrease in the number of T cells in an experimental model of respiratory allergy, suggesting that the plant can be delivered via inhalation route to treat allergic asthma.


Subject(s)
Cissampelos/chemistry , Hypersensitivity/drug therapy , Plant Extracts/pharmacology , T-Lymphocytes/drug effects , Administration, Inhalation , Alkaloids/pharmacology , Alkaloids/therapeutic use , Animals , Benzylisoquinolines/pharmacology , CD3 Complex , Down-Regulation , Eosinophils/immunology , Female , Immunoglobulin E/blood , Inflammation/chemically induced , Inflammation/drug therapy , Lung/drug effects , Lung/pathology , Mice , Mice, Inbred BALB C , Ovalbumin , Plant Extracts/therapeutic use , Pleurisy/chemically induced , Pleurisy/drug therapy , Rats , Rats, Wistar , T-Lymphocytes/immunology
6.
FEBS J ; 279(15): 2610-23, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22621751

ABSTRACT

Lipids form a diverse group of water-insoluble molecules that include triacylglycerides, phosphoglycerides, sterols and sphingolipids. They play several important roles at cellular and organismal levels. Fatty acids are the major building blocks for the synthesis of triacylglycerides, which are mainly used for energy storage. Phosphoglycerides, together with sterols and sphingolipids, represent the major structural components of biological membranes. Lipids can also have important roles in signalling, functioning as second messengers and as hormones. There is increasing evidence that cancer cells show specific alterations in different aspects of lipid metabolism. These alterations can affect the availability of structural lipids for the synthesis of membranes, the synthesis and degradation of lipids that contribute to energy homeostasis and the abundance of lipids with signalling functions. Changes in lipid metabolism can affect numerous cellular processes, including cell growth, proliferation, differentiation and motility. This review will examine some of the alterations in lipid metabolism that have been reported in cancer, at both cellular and organismal levels, and discuss how they contribute to different aspects of tumourigenesis.


Subject(s)
Lipid Metabolism , Neoplasms/metabolism , Animals , Cell Proliferation , Cell Transformation, Neoplastic , Energy Metabolism , Homeostasis , Humans , Hypoxia/metabolism , Neoplasm Proteins/genetics , Neoplasm Proteins/metabolism , Neoplasms/genetics , Neoplasms/pathology , Oncogenes , Oxidative Stress , Signal Transduction , Sterol Regulatory Element Binding Proteins/genetics , Sterol Regulatory Element Binding Proteins/metabolism
7.
Cancer Discov ; 2(4): 328-43, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22576210

ABSTRACT

UNLABELLED: Alterations in metabolic activity contribute to the proliferation and survival of cancer cells. We investigated the effect of siRNA-mediated gene silencing of 222 metabolic enzymes, transporters, and regulators on the survival of 3 metastatic prostate cancer cell lines and a nonmalignant prostate epithelial cell line. This approach revealed significant complexity in the metabolic requirements of prostate cancer cells and identified several genes selectively required for their survival. Among these genes was 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 (PFKFB4), an isoform of phosphofructokinase 2 (PFK2). We show that PFKFB4 is required to balance glycolytic activity and antioxidant production to maintain cellular redox balance in prostate cancer cells. Depletion of PFKFB4 inhibited tumor growth in a xenograft model, indicating that it is required under physiologic nutrient levels. PFKFB4 mRNA expression was also found to be greater in metastatic prostate cancer compared with primary tumors. Taken together, these results indicate that PFKFB4 is a potential target for the development of antineoplastic agents. SIGNIFICANCE: Cancer cells undergo several changes in their metabolism that promote growth and survival. Using an unbiased functional screen, we found that the glycolytic enzyme PFKFB4 is essential for prostate cancer cell survival by maintaining the balance between the use of glucose for energy generation and the synthesis of antioxidants. Targeting PFKFB4 may therefore present new therapeutic opportunities.


Subject(s)
Metabolomics , Phosphofructokinase-2/metabolism , Prostatic Neoplasms/metabolism , AMP-Activated Protein Kinases/genetics , AMP-Activated Protein Kinases/metabolism , Allosteric Regulation , Apoptosis/genetics , Cell Line, Tumor , Cell Survival/genetics , Cluster Analysis , Enzyme Activation , Gene Expression Profiling , Gene Silencing , Glycolysis , Humans , Male , Oxidation-Reduction , Phosphofructokinase-2/genetics , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Tumor Burden/genetics
8.
Int Immunopharmacol ; 13(2): 148-55, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22480776

ABSTRACT

BACKGROUND: Cissampelos sympodialis Eichl. (Menispermaceae) is a plant found in Northeastern and Southeast of Brazil and hot water infusion of C. sympodialis root bark is largely used in the indigenous and folk medicine to treat several inflammatory disorders, including asthma. Asthma is a chronic inflammatory allergic disease characterized by airway hyperreactivity (AHR), eosinophil tissue infiltration and lung remodeling. The aim of this study was to evaluate the therapeutic effect of C. sympodialis and its isolated alkaloid warifteine on allergen triggered airway hyperreactivity (AHR) and lung remodeling in murine model of asthma. METHODOLOGY/PRINCIPAL FINDINGS: The oral pre-treatment with C. sympodialis or warifteine inhibited allergen-induced AHR to inhaled methacholine and IL-13 levels in the bronchoalveolar lavage (BAL). In order to investigate the therapeutic potential of C. sympodialis and warifteine, animals were treated 1h after the last ovalbumin (OVA) challenge in sensitized animals. Similarly to the pre-treatment, post-treatment with warifteine was effective to inhibit significantly AHR to inhaled methacholine and to reduce IL-13 levels in the BAL. In addition, oral pre- or post-treatments with C. sympodialis or warifteine reduced OVA-induced eosinophil tissue infiltration, mucus production and subepithelial fibrosis to values similar to nonallergic controls. CONCLUSIONS: Our data show the anti-allergic and immunoregulatory properties of C. sympodialis, acting mostly through the active compound warifteine, to inhibit the airway hyperreactivity and lung remodeling through a mechanism at least partially dependent of IL-13 and eosinophil inhibition. Therefore placing warifteine as an interesting therapeutic candidate in allergic inflammation and corroborating the folk medicine use of C. sympodialis as anti-allergic plant.


Subject(s)
Alkaloids/therapeutic use , Asthma/drug therapy , Cissampelos/chemistry , Phytotherapy , Alkaloids/chemistry , Animals , Asthma/immunology , Asthma/pathology , Asthma/physiopathology , Bronchial Hyperreactivity/drug therapy , Bronchial Hyperreactivity/physiopathology , Bronchoalveolar Lavage Fluid/immunology , Collagen/metabolism , Disease Models, Animal , Eosinophils/drug effects , Eosinophils/pathology , Female , Humans , Interleukin-13/biosynthesis , Lung/drug effects , Lung/pathology , Mice , Mice, Inbred BALB C , Ovalbumin/immunology , Plants, Medicinal/chemistry , Respiratory Hypersensitivity/drug therapy , Respiratory Hypersensitivity/physiopathology
9.
N Engl J Med ; 366(10): 883-892, 2012 Mar 08.
Article in English | MEDLINE | ID: mdl-22397650

ABSTRACT

BACKGROUND: Intratumor heterogeneity may foster tumor evolution and adaptation and hinder personalized-medicine strategies that depend on results from single tumor-biopsy samples. METHODS: To examine intratumor heterogeneity, we performed exome sequencing, chromosome aberration analysis, and ploidy profiling on multiple spatially separated samples obtained from primary renal carcinomas and associated metastatic sites. We characterized the consequences of intratumor heterogeneity using immunohistochemical analysis, mutation functional analysis, and profiling of messenger RNA expression. RESULTS: Phylogenetic reconstruction revealed branched evolutionary tumor growth, with 63 to 69% of all somatic mutations not detectable across every tumor region. Intratumor heterogeneity was observed for a mutation within an autoinhibitory domain of the mammalian target of rapamycin (mTOR) kinase, correlating with S6 and 4EBP phosphorylation in vivo and constitutive activation of mTOR kinase activity in vitro. Mutational intratumor heterogeneity was seen for multiple tumor-suppressor genes converging on loss of function; SETD2, PTEN, and KDM5C underwent multiple distinct and spatially separated inactivating mutations within a single tumor, suggesting convergent phenotypic evolution. Gene-expression signatures of good and poor prognosis were detected in different regions of the same tumor. Allelic composition and ploidy profiling analysis revealed extensive intratumor heterogeneity, with 26 of 30 tumor samples from four tumors harboring divergent allelic-imbalance profiles and with ploidy heterogeneity in two of four tumors. CONCLUSIONS: Intratumor heterogeneity can lead to underestimation of the tumor genomics landscape portrayed from single tumor-biopsy samples and may present major challenges to personalized-medicine and biomarker development. Intratumor heterogeneity, associated with heterogeneous protein function, may foster tumor adaptation and therapeutic failure through Darwinian selection. (Funded by the Medical Research Council and others.).


Subject(s)
Carcinoma, Renal Cell/genetics , Evolution, Molecular , Genetic Heterogeneity , Kidney Neoplasms/genetics , Phenotype , Biomarkers, Tumor , Biopsy , Carcinoma, Renal Cell/pathology , Carcinoma, Renal Cell/secondary , Chromosome Aberrations , Everolimus , Exome , Genetic Heterogeneity/drug effects , Humans , Immunosuppressive Agents/pharmacology , Kidney/pathology , Kidney Neoplasms/pathology , Mutation , Neoplasm Metastasis/genetics , Neoplasm Metastasis/pathology , Phylogeny , Ploidies , Polymorphism, Single Nucleotide , Sequence Analysis, DNA , Sirolimus/analogs & derivatives , Sirolimus/pharmacology
10.
J Pathol ; 227(2): 146-56, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22362593

ABSTRACT

Clear cell renal cell carcinoma (ccRCC) is the most common pathological subtype of kidney cancer. Here, we integrated an unbiased genome-wide RNA interference screen for ccRCC survival regulators with an analysis of recurrently overexpressed genes in ccRCC to identify new therapeutic targets in this disease. One of the most potent survival regulators, the monocarboxylate transporter MCT4 (SLC16A3), impaired ccRCC viability in all eight ccRCC lines tested and was the seventh most overexpressed gene in a meta-analysis of five ccRCC expression datasets. MCT4 silencing impaired secretion of lactate generated through glycolysis and induced cell cycle arrest and apoptosis. Silencing MCT4 resulted in intracellular acidosis, and reduction in intracellular ATP production together with partial reversion of the Warburg effect in ccRCC cell lines. Intra-tumoural heterogeneity in the intensity of MCT4 protein expression was observed in primary ccRCCs. MCT4 protein expression analysis based on the highest intensity of expression in primary ccRCCs was associated with poorer relapse-free survival, whereas modal intensity correlated with Fuhrman nuclear grade. Consistent with the potential selection of subclones enriched for MCT4 expression during disease progression, MCT4 expression was greater at sites of metastatic disease. These data suggest that MCT4 may serve as a novel metabolic target to reverse the Warburg effect and limit disease progression in ccRCC.


Subject(s)
Carcinoma, Renal Cell/genetics , Glycolysis/genetics , Kidney Neoplasms/genetics , Monocarboxylic Acid Transporters/genetics , Muscle Proteins/genetics , RNA Interference , Apoptosis , Carcinoma, Renal Cell/mortality , Carcinoma, Renal Cell/pathology , Cell Cycle Checkpoints , Cell Line, Tumor , Cell Proliferation , Cell Survival , Disease-Free Survival , Genetic Predisposition to Disease , Genome-Wide Association Study , Humans , Hydrogen-Ion Concentration , Kaplan-Meier Estimate , Kidney Neoplasms/metabolism , Kidney Neoplasms/mortality , Kidney Neoplasms/pathology , Lactic Acid/metabolism , Phenotype , Prognosis , RNA, Messenger/metabolism , Time Factors , Transfection
11.
Rev Med Virol ; 21(5): 285-300, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21726011

ABSTRACT

Viral infections cause a major stress in host cells. The cellular responses to stress are mediated by p53, which by deregulation of cell cycle and apoptosis, may also be part of the host cell reaction to fight infections. Therefore, during evolutionary viral adaptation to host organisms, viruses have developed strategies to manipulate host cell p53 dependent pathways to facilitate their viral life cycles. Thus, interference with p53 function is an important component in viral pathogenesis. Many viruses have proteins that directly affect p53, whereas others alter the regulation of p53 in an indirect manner, mediated by Hdm2 or Akt, or induction of interferon. Rescue of p53 activity is becoming an area of therapeutic development in oncology. It might be feasible that manipulation of p53 mediated responses can become a therapeutic option to limit viral replication or dissemination. In this report, the mechanisms by which viral proteins manipulate p53 responses are reviewed, and it is proposed that a pharmacological rescue of p53 functions might help to control viral infections.


Subject(s)
Host-Pathogen Interactions , Tumor Suppressor Protein p53/metabolism , Viral Proteins/metabolism , Virus Physiological Phenomena , Virus Replication , Viruses/growth & development , Humans , Tumor Suppressor Protein p53/antagonists & inhibitors , Virus Diseases/therapy
12.
Biochem Soc Trans ; 39(2): 495-9, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21428927

ABSTRACT

In recent years several reports have linked mTORC1 (mammalian target of rapamycin complex 1) to lipogenesis via the SREBPs (sterol-regulatory-element-binding proteins). SREBPs regulate the expression of genes encoding enzymes required for fatty acid and cholesterol biosynthesis. Lipid metabolism is perturbed in some diseases and SREBP target genes, such as FASN (fatty acid synthase), have been shown to be up-regulated in some cancers. We have previously shown that mTORC1 plays a role in SREBP activation and Akt/PKB (protein kinase B)-dependent de novo lipogenesis. Our findings suggest that mTORC1 plays a crucial role in the activation of SREBP and that the activation of lipid biosynthesis through the induction of SREBP could be part of a regulatory pathway that co-ordinates protein and lipid biosynthesis during cell growth. In the present paper, we discuss the increasing amount of data supporting the potential mechanisms of mTORC1-dependent activation of SREBP as well as the implications of this signalling pathway in cancer.


Subject(s)
Proteins/physiology , Sterol Regulatory Element Binding Proteins/metabolism , Animals , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Humans , Mechanistic Target of Rapamycin Complex 1 , Models, Biological , Multiprotein Complexes , Oncogene Protein v-akt/physiology , Protein Processing, Post-Translational/physiology , Proteins/metabolism , Signal Transduction/genetics , Signal Transduction/physiology , Sterol Regulatory Element Binding Proteins/genetics , TOR Serine-Threonine Kinases , Transcription Factors/genetics , Transcription Factors/metabolism
13.
Adv Enzyme Regul ; 51(1): 280-90, 2011.
Article in English | MEDLINE | ID: mdl-21093473

ABSTRACT

The SREBP family of transcription factors regulates the expression of genes involved in fatty acid and cholesterol biosynthesis. The activation of SREBP transcription factors requires proteolytic cleavage of the inactive precursor and nuclear translocation of the mature form of the protein. It has been shown that nuclear accumulation of the mature form of SREBP1 is induced in response to activation of the serine/threonine kinase Akt, an important effector of the Ras/PI3-kinase signalling pathway. Activation of SREBP by Akt depends on the mammalian target of rapamycin complex 1 (mTORC1) but the exact mechanism of this activation remains unclear. We have investigated whether ablation of different signalling molecules downstream of mTORC1 affects expression of SREBP targets genes. We could show that inhibition of S6-kinases 1 and 2 expression using RNA interference did not block induction of expression of fatty acid synthase (FASN) or ATP-citrate lyase (ACLY) following activation of Akt in human retinal pigment epithelial cells. Furthermore, accumulation of mature SREBP1 was not inhibited after combined silencing of S6-kinases 1 and 2. Genetic ablation of both kinases also did not prevent the formation of mature SREBP1 in mouse embryonic fibroblasts. Taken together, these results suggest that S6-kinases 1 and 2 are dispensable for the induction of SREBP processing in the experimental systems used here.


Subject(s)
Ribosomal Protein S6 Kinases/genetics , Sterol Regulatory Element Binding Protein 1/metabolism , Animals , Cells, Cultured , Humans , Isoenzymes/genetics , Isoenzymes/metabolism , Mechanistic Target of Rapamycin Complex 1 , Mice , Multiprotein Complexes , Proteins/genetics , Proteins/metabolism , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-akt/metabolism , RNA Interference , Ribosomal Protein S6 Kinases/metabolism , Sterol Regulatory Element Binding Protein 1/genetics , TOR Serine-Threonine Kinases
14.
Biochem Soc Trans ; 37(Pt 1): 278-83, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19143646

ABSTRACT

Cell growth requires co-ordinated regulation of processes that provide metabolites for the synthesis of macromolecules such as proteins and membrane lipids. In recent years, a lot of emphasis has been placed on the activation of protein synthesis by mTORC1 (mammalian target of rapamycin complex 1). The contribution of anabolic pathways other than protein synthesis has only been considered recently. In the present paper, we discuss recent findings regarding the contribution of transcriptional regulation of lipogenesis genes by the SREBP (sterol-regulatory-element-binding protein) transcription factor, a central regulator of expression of lipogenic genes, to the control of cell size in vitro and cell and organ size in vivo.


Subject(s)
Cell Size , Sterol Regulatory Element Binding Proteins/metabolism , Transcription Factors/metabolism , Animals , Cell Proliferation , Humans , Organ Size , Proto-Oncogene Proteins c-akt/metabolism
15.
Cell Metab ; 8(3): 224-36, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18762023

ABSTRACT

Cell growth (accumulation of mass) needs to be coordinated with metabolic processes that are required for the synthesis of macromolecules. The PI3-kinase/Akt signaling pathway induces cell growth via activation of complex 1 of the target of rapamycin (TORC1). Here we show that Akt-dependent lipogenesis requires mTORC1 activity. Furthermore, nuclear accumulation of the mature form of the sterol responsive element binding protein (SREBP1) and expression of SREBP target genes was blocked by the mTORC1 inhibitor rapamycin. We also show that silencing of SREBP blocks Akt-dependent lipogenesis and attenuates the increase in cell size in response to Akt activation in vitro. Silencing of dSREBP in flies caused a reduction in cell and organ size and blocked the induction of cell growth by dPI3K. Our results suggest that the PI3K/Akt/TOR pathway regulates protein and lipid biosynthesis in an orchestrated manner and that both processes are required for cell growth.


Subject(s)
Drosophila Proteins/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Sterol Regulatory Element Binding Protein 1/metabolism , Transcription Factors/metabolism , Animals , Cell Enlargement/drug effects , Cell Nucleus/metabolism , Cells, Cultured , Drosophila , Gene Expression/drug effects , Lipids/biosynthesis , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , RNA Interference , Signal Transduction/drug effects , Sirolimus/pharmacology
16.
PLoS One ; 3(2): e1660, 2008 Feb 20.
Article in English | MEDLINE | ID: mdl-18286207

ABSTRACT

BACKGROUND: Cellular biological responses to specific stimulation are determined by a balance among signaling pathways. Protein interactions are likely to modulate these pathways. Vaccinia-related kinase-2 (VRK2) is a novel human kinase that can modulate different signaling pathways. PRINCIPAL FINDINGS: We report that in vivo, the activity of JIP1-JNK complexes is downregulated by VRK2 in response to interleukin-1beta. Also the reduction of endogenous VRK2 with shRNA increases the transcriptional response to IL-1beta. The JIP1 scaffold protein assembles three consecutive members of a given MAPK pathway forming signaling complexes and their signal can be modulated by interactions with regulatory proteins that remain to be identified. Knocking-down JIP1 with siRNA resulted in elimination of the AP1 transcriptional response to IL-1beta. VRK2, a member of novel Ser-Thr kinase family, is able to stably interact with JIP1, TAK1 and MKK7, but not JNK, and can be isolated forming oligomeric complexes with different proportions of TAK1, MKK7beta1 and JNK. JIP1 assembles all these proteins in an oligomeric signalosome. VRK2 binding to the JIP1 signalosome prevents the association of JNK and results in a reduction in its phosphorylation and downregulation of AP1-dependent transcription. CONCLUSIONS/SIGNIFICANCE: This work suggests that the intracellular level of VRK2 protein can modulate the flow through a signaling pathway and alter the response from a receptor that can be distributed by more than one pathway, and thus contribute to the cellular specificity of the response by forming alternative signaling complexes. Furthermore, the effect might be more general and affect other signaling routes assembled on the JIP1 scaffold protein for which a model is proposed.


Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Interleukin-1beta/physiology , JNK Mitogen-Activated Protein Kinases/metabolism , Protein Serine-Threonine Kinases/metabolism , Transcription, Genetic , Down-Regulation/genetics , Humans , Phosphorylation , Protein Binding , Signal Transduction , Transcription Factor AP-1
17.
J Virol ; 80(15): 7667-75, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16840345

ABSTRACT

Viruses have to adjust to the host cell to guarantee their life cycle and survival. This aspect of the virus-host cell interaction is probably performed by viral proteins, such as serine-threonine kinases, that are present early during infection. Vaccinia virus has an early Ser-Thr kinase, B1R, which, although required for successful viral infection, is poorly characterized regarding its effects on cellular proteins, and thus, its potential contribution to pathogenesis is not known. Signaling by mitogen-activated protein kinase (MAPK) is mediated by the assembly of complexes between these kinases and the JIP scaffold proteins. To understand how vaccinia virus B1R can affect the host, its roles in the cellular signaling by MAPK complexes and c-Jun activation have been studied. Independently of its kinase activity, B1R can interact with the central region of the JIP1 scaffold protein. The B1R-JIP1 complex increases the amount of MAPK bound to JIP1; thus, MKK7 and TAK1 either bind with higher affinity or bind more stably to JIP1, while there is an increase in the phosphorylation state of JNK bound to JIP1. The functional consequence of these more stable interactions is an increase in the activity of transcription factors, such as c-Jun, that respond to these complexes. Furthermore, B1R is also able to directly phosphorylate c-Jun in residues different from those targeted by JNK and, thus, B1R can also cooperate by an independent route in c-Jun activation. Vaccinia virus B1R can thus modulate the signaling of pathways that respond to cellular stress.


Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins c-jun/metabolism , Signal Transduction , Vaccinia virus/enzymology , Viral Proteins/metabolism , Animals , Chlorocebus aethiops , Enzyme Activation , HeLa Cells , Humans , Kidney Tubules/cytology , Kidney Tubules/metabolism , MAP Kinase Kinase Kinases/metabolism , Mitogen-Activated Protein Kinases/metabolism , Phosphorylation , Protein Binding
18.
Int Immunopharmacol ; 6(7): 1152-60, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16714219

ABSTRACT

Development of new agents capable of regulating eosinophilic inflammation can uncover novel therapeutic approaches for the treatment of allergic diseases, such as asthma. Here, we evaluated the anti-allergic properties of an extract of the Brazilian Menispermaceae Cissampelos sympodialis, focusing on its effects on allergic eosinophilia. By studying two models of allergic inflammation, an asthma model and the allergic pleurisy in actively sensitized Balb/c mice, we observed that the oral pre-treatment with C. sympodialis reduced pleural eosinophil influx triggered by allergen challenge in a dose-dependent manner. The mechanism involved in C. sympodialis inhibitory effect appeared to be independent of a direct effect on eosinophil locomotory machinery, but depend on a blockage of eotaxin production, a key eosinophil chemoattractant with important roles in allergic reactions. C. sympodialis was also able to affect eosinophil activation, as attested by its ability of inhibiting formation of new cytoplasmic lipid bodies and the secretion of cysteinyl leukotrienes. The alkaloid warifteine isolated from the C. sympodialis extract represents an active component responsible for the anti-eosinophilic effects of the extract, since warifteine was able to reproduce C. sympodialis inhibitory effects on allergic eosinophilia and cysteinyl leukotrienes production. Of interest, C. sympodialis and warifteine post-treatments also effectively inhibited eosinophilic reaction observed after allergic challenge. Therefore, C. sympodialis/warifteine may be a promising anti-allergic therapy, inasmuch as it presents potent anti-eosinophil and anti-leukotrienes activities.


Subject(s)
Alkaloids/pharmacology , Anti-Allergic Agents/pharmacology , Asthma/drug therapy , Cissampelos/chemistry , Pleurisy/drug therapy , Allergens/pharmacology , Animals , Bronchoalveolar Lavage Fluid/chemistry , Bronchoalveolar Lavage Fluid/cytology , Cells, Cultured , Chemokine CCL11 , Chemokines, CC/analysis , Disease Models, Animal , Eosinophils/drug effects , Eosinophils/immunology , Female , Humans , Leukocyte Count , Leukotrienes/analysis , Male , Mice , Mice, Inbred BALB C , Ovalbumin/pharmacology , Plant Extracts/pharmacology , Plant Leaves/chemistry , Pulmonary Eosinophilia/drug therapy
19.
Mol Cancer Res ; 4(3): 177-85, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16547155

ABSTRACT

The vaccinia-related kinase (VRK) proteins are a new family with three members in the human kinome. The VRK1 protein phosphorylates several transcription factors and has been postulated to be involved in regulation of cell proliferation. In normal squamous epithelium, VRK1 is expressed in the proliferation area. Because VRK1 can stabilize p53, the expression of the VRK1 protein was analyzed in the context of the p53 pathway and the proliferation phenotype in a series of 73 head and neck squamous cell carcinomas. VRK1 protein level positively correlated with p53 response proteins, particularly hdm2 and p21. The VRK1 protein also correlated positively with several proteins associated with proliferation, such as cyclin-dependent kinase 2 (CDK2), CDK6, cdc2, cyclins B1 and A, topoisomerase II, survivin, and Ki67. The level of VRK1 protein behaves like a proliferation marker in this series of head and neck squamous cell carcinomas. To identify a possible regulatory role for VRK1 and because it regulates gene transcription, the promoters of two genes were studied, CDK2 and SURVIVIN, whose proteins correlated positively with VRK1. VRK1 increases the activity of both the CDK2 and SURVIVIN gene promoters. The expression of VRK1 was analyzed in the context of regulators of the G1-S transition. VRK1 protein levels increase in response to E2F1 and are reduced by retinoblastoma and p16. These data suggest that VRK1 might play a role in cell cycle regulation and is likely to represent the beginning of a new control mechanism of cell cycle, particularly late in the G1-S phase.


Subject(s)
Carcinoma, Squamous Cell/pathology , Cyclin-Dependent Kinase 2/genetics , Gene Expression Regulation, Neoplastic , Head and Neck Neoplasms/pathology , Microtubule-Associated Proteins/genetics , Neoplasm Proteins/genetics , Proteins/metabolism , Biomarkers, Tumor/analysis , Carcinoma, Squamous Cell/chemistry , Carcinoma, Squamous Cell/genetics , Cell Cycle Proteins/genetics , Cell Cycle Proteins/metabolism , Cell Proliferation , E2F1 Transcription Factor/metabolism , Head and Neck Neoplasms/chemistry , Head and Neck Neoplasms/genetics , Humans , Immunohistochemistry , Inhibitor of Apoptosis Proteins , Intracellular Signaling Peptides and Proteins , Phenotype , Promoter Regions, Genetic , Protein Serine-Threonine Kinases , Proteins/analysis , Signal Transduction , Survivin , Tumor Suppressor Protein p53/metabolism
20.
Virology ; 328(2): 254-65, 2004 Oct 25.
Article in English | MEDLINE | ID: mdl-15464845

ABSTRACT

Poxvirus infection has a strong effect on cellular functions. To understand viral pathogenesis, it is necessary to know how viral proteins interact with host proteins. The B1R kinase is an early viral gene required for vaccinia virus DNA synthesis and replication, but no cellular substrate is known for this viral kinase. B1R is able to hyperphosphorylate p53 in several residues in the N-terminal transactivation domain, including Ser15 and Thr18. B1R does not phosphorylate Mdm2. B1R promotes an increase in p53 ubiquitination and a reduction of p53 acetylation by p300. The over-expressed B1R protein induces the degradation of p53 in a concentration-dependent manner and is lost when Ser15 and Th18 are changed to alanine or when the B1R kinase is inactivated by introducing the K149Q substitution. The B1R-induced downregulation of p53 requires Mdm2. The hyperphosphorylated p53 is transcriptionally active, and this activity also falls as B1R increases. The BAX gene promoter is more sensitive to this reduction of transcription than p21 or 14-3-3 gene promoters. This effect of B1R on p53 can be one of the mechanisms by which vaccinia virus exerts its role in infected cells.


Subject(s)
Nuclear Proteins/metabolism , Protein Serine-Threonine Kinases/metabolism , Proto-Oncogene Proteins/metabolism , Tumor Suppressor Protein p53/metabolism , Vaccinia virus/metabolism , Viral Proteins/metabolism , Alanine , Amino Acid Substitution , Animals , Cell Line , Down-Regulation , Mice , Phosphorylation , Protein Structure, Tertiary , Proto-Oncogene Proteins c-mdm2 , Serine , Threonine , Tumor Suppressor Protein p53/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...